Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 21, 2005. The report primarily discloses changes in directors' interests in ordinary shares and announces a change to the composition of the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance and share transaction details rather than financial performance.
Specific share transaction prices noted in the text include:
- Sale price on December 17, 2004: £11.69 per share.
- Purchase price on January 13, 2005 (dividend reinvestment): £12.43 per share.
- Purchase price on January 17, 2005 (dividend reinvestment): £12.15 per share.
Material Changes
The filing details several share movements involving employee trusts and plans:
- January 20, 2005: The GSK Trust transferred 1,792 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- December 17, 2004: 973 ordinary shares were sold on behalf of a participant in the SmithKline Beecham Bonus Investment Plan.
- January 13, 2005: 1,127 ordinary shares were purchased for the SmithKline Beecham Bonus Investment Plan following dividend reinvestment.
- January 17, 2005: 929 ordinary shares were transferred to participants in the SmithKline Beecham Unapproved Share Match Plan, and 7,560 shares were purchased for the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Governance Changes
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary corporate action announced is:
- Audit Committee Appointment: Sir Deryck Maughan was appointed as a member of the Audit Committee with immediate effect as of January 21, 2005.
- Committee Membership: The updated Audit Committee consists of Chairman Dr. Ronaldo Schmitz, Sir Deryck Maughan, Sir Ian Prosser, and Sir Robert Wilson.
Investor Verification Checklist
- Verify the impact of the new Audit Committee member, Sir Deryck Maughan, on oversight procedures.
- Confirm the total number of shares held by directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe through the GSK Trust.
- Review the full 20-F annual report for comprehensive financial metrics, as this 6-K filing does not contain them.
- Check subsequent filings for any further changes to the Board or Committee structures.